BioMedWire Stocks

Why it is Crucial to Prepare Healthcare Data for Use in AI Models

The rate at which AI is being integrated in healthcare is accelerating. However, data quality is often lacking, and this reduces the effectiveness of many AI solutions tailored to the healthcare industry. Given that healthcare data is often siloed, the vast majority of this data is unstructured. This can pose challenges in the use of this data for AI models since the insights extracted could be biased or have other defects.

Data needs to be consistent in the way it is presented, its quality must be high and the formats need to be standardized. Otherwise, the data could be misinterpreted or the AI model can miss potentially useful insights.

Other challenges with medical data that ought to be addressed before the data is used by AI models include inaccuracies in the data, lack of validity and incomplete data. These issues of data quality can result in the model being misled to the extent that the AI perceives patterns which don’t exist in reality. Addressing these challenges before this data is deployed for use by an AI model is therefore vital.

The biggest hurdle in data preparation, especially healthcare data, lies in the unstructured or semi-structured nature of that data. A key step to fixing this defect is to get that raw information and transform it so that it matches an existing industry standard. For example, you could take a clinical terminology tool and use it to codify the available clinical notes so that this data aligns with an existing industry standard.

There are six core attributes which one must ensure when preparing their data for use by an AI system. These are timeliness, consistency, completeness, data integrity, validity and accuracy. Healthcare entities that keep an eye on these elements have a high chance of minimizing errors when this data is used by an AI system and the use of that data will be efficient.

Data governance is key to ensuring that all the data used is good and appropriate. For example, the data governance system has to have mechanisms through which lab data can be verified to confirm that it conforms to an existing industry standard. This can prevent wrong codes finding their way into the data being relied upon to train an AI model or seek actionable insights. The data governance system should also have a mechanism to incorporate all the coding system updates issued from time to time so that the data remains classified in a way that stays relevant as codes change or are updated. This plugs all gaps and eliminates bias in the insights obtained.

Companies like HealthLynked Corp. (OTCQB: HLYK) that specialize in offering digital healthcare data solutions may have a lot of lessons that other healthcare-linked organizations can learn from in order to make their data AI-ready.

NOTE TO INVESTORS: The latest news and updates relating to HealthLynked Corp. (OTCQB: HLYK) are available in the company’s newsroom at https://ibn.fm/HLYK

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in…

2 days ago

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential…

4 days ago

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…

4 days ago

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…

5 days ago

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…

1 week ago

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…

1 week ago